M
ajor randomized controlled trials conducted during the 1990s demonstrated the importance of tightly and consistently managing A1C levels among type 1 and type 2 diabetic patients (1,2). A follow-up of the Diabetes Control and Complications Trial (DCCT) reaffirmed the value of glycemic control because microvascular complications remained lower among intervention participants 7 years after the trial concluded (3). These and other studies highlighted the central role of glycemic control in the management of diabetes. Accordingly, professional associations, including the American Association of Clinical Endocrinologists (AACE), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD), established clinical guidelines in the range of 6.5-7.0% to motivate health professionals and patients to consistently manage blood glucose levels (4,5). The National Diabetes Quality Improvement Alliance, a private-public entity, developed national performance measures to monitor glycemic control and other diabetes care processes and outcomes.
Despite the emphasis on glycemic control, evidence of improvement in A1C control over time remains scant. In a recent study comparing nationally representative data from 1999 -2002 with comparable data from 1988 -1994, the mean A1C level declined from 7.8 to 7.7% (not significant at the 5% level) among adults with self-reported diabetes (6). The study found some evidence suggesting an improvement in poorly controlled A1C; the percentage of patients with A1C Ͼ9.0% decreased from 24.5 to 20.6%, but this decline was not significant at the 5% level. Other studies have also shown little or no time trend in A1C levels (7,8); one study (8) reported that the rate of glycemic control (A1C Ͻ7.0%) fell from 44.5% in 1988 -1994 to 35.8% in 1999 -2000. Given the attention on glycemic control in clinical disease management and public health programs during the past decade, these observations are both concerning and surprising. In this study, we examined recent national trends in glycemic control among adults with diagnosed diabetes.
RESEARCH DESIGN AND
METHODS -We examined data from the National Health and Nutrition Examination Survey (NHANES), the same data source used in the previous studies (6 -8). NHANES is a nationally representative, population-based survey designed to collect information on the health and nutrition of the U.S. civilian noninstitutionalized population. NHANES is now an ongoing survey, with results released in 2-year waves. Survey details are described elsewhere (9 -11). Participants answer a household interview, and most complete clinical examinations in a mobile examination center.
We focused on the 1999 -2000, 2001 -2002 , and 2003 -2004 waves. This focus allowed us to use the most recent data to examine recent trends in glycemic control. We limited our analysis to adults (aged Ն18 years) who reported a previous diagnosis of diabetes by a health care professional and who received an A1C measurement.
Blood specimens were processed, stored, and shipped to the Diabetes Diagnostic Laboratory at the University of Mis-
souri-Columbia for analysis of A1C, using Primus CLC330 and Primus CLC385. The system was standardized to the reference method used in the DCCT. We included data from 403, 448, and 482 individuals in, respectively, the 1999 -2000, 2001-2002, and 2003-2004 waves.
We estimated mean A1C levels for individuals reporting diagnosed diabetes for each of three NHANES data waves, as well as the percentages of the population with A1C Ͻ7.0, Ͻ8.0, and Ͻ9.0%. We applied multivariate regression to test whether A1C levels differed among NHANES waves after controlling for age, sex, race/ethnicity, education, BMI, insurance status, income, and duration of diab e t e s . W e e s t i m a t e d a s e c o n d specification that also included treatment variables (diabetes pills only, insulin only, and both pills and insulin; the omitted treatment variable was diet only).
We RESULTS -The characteristics of individuals reporting diabetes and receiving an A1C measurement were relatively consistent among the NHANES waves (Table  1) . Education was the only characteristic with significant changes between 1999 -2000 and the last two waves.
Mean A1C levels among study participants with diagnosed diabetes were (Table  2) . Improvements in mean A1C levels were observed for most subgroups of the population during the later waves, with significant univariate reductions for individuals aged Ն65 years, women, all racial/ethnic groups except Hispanic, those with more than a high school education, those with BMI Ͻ30 and BMI Ն30 kg/m 2 , those of both income levels, those with insurance, those with diabetes duration Ͻ5 years and between 5 and 14 years, those who formerly or never smoked, and those treated with diabetes pills only or diet only. Only Hispanics had a higher mean A1C in 2003-2004 than in 1999 -2000.
The A1C interval data show a corresponding shift to the left (Table 2 and The multivariate regression results in- (Table 3 ; no treatment variables included). After controls for other factors, the differences in waves were less than those in univariate means. However The treatment effects were associated with higher A1C levels, probably because the treatments were prescribed when A1C was not controlled by diet only. The multivariate logistic results indicate corresponding improvements over time in the benchmarks for glycemic control (Table 4) Health plans embraced multifaceted disease management programs to improve care and reduce A1C levels. These plans were targeted to health systems and providers as well as to patients with diabetes. National public health awareness programs, including those promoted by the National Diabetes Education Program, the National Diabetes Quality Improvement Alliance, and several professional organizations (ADA, EASD, and AACE), emphasized improved glycemic control along with cardiovascular risk factor control. Improved measurement and reporting of diabetes care in health plans may have further motivated glycemic control efforts. At the same time, new drugs became available in the U.S., including metformin (available by brand name since 1995 and as a generic drug since 2002) and the thiazolidinediones (available in current brands since 1999). Patient adherence to therapy may have increased, possibly due to improved diabetes education and/or fewer side effects from medi- cation. Medicare also increased coverage for diabetes-related supplies during this period. Whether these or other factors can explain the decrease in mean A1C levels is a topic for future research.
Our findings will be strengthened if they are confirmed by analyses of other datasets and future NHANES waves. Nonetheless, our analysis has certain strengths. The NHANES sample is nationally representative and has a sufficient sample size to detect differences between time periods. Uniform methods were used for the diabetes section of NHANES, and A1C values were assessed by a single laboratory with close attention to quality of control and measurement. Our results are significant even after we controlled for demographic variables in the multivariate analysis. The fact that mean A1C was lower in 2001-2002 than in 1999 -2000 and then lower still in 2003-2004, both for the entire sample and for most demographic groups (Table 2) , further suggests that there was a real trend in A1C levels.
Our analysis has at least two potential limitations. First, diabetes status was selfreported and, in the absence of a clinical patient history, some individuals in the sample might not have had diabetes and would thus be expected to have A1C levels near normal. However, previous studies have suggested that the self-reported diabetes variable has high reproducibility and validity (14, 15) , and there is little reason to believe that errors in self-reporting would increase over time. Second, although respondents reported time since diagnosis of diabetes, information on diabetes onset is not available. It is possible that earlier detection of diabetes in recent years could bias the results toward lower mean A1C. On the other hand, we found a time trend toward lower A1C levels for all categories of years of diagnosed duration, and the percentage of individuals with duration of diagnosed diabetes Ͻ5 years changed little among NHANES waves. We also controlled for time since diagnosis in the regression analyses. However, these results do not fully resolve the issue of whether diagnosis has been occurring closer to onset.
Our findings are encouraging for the long-term outcomes of patients with diabetes. Hazard model estimates based on 10-year outcomes observed in UKPDS data suggest that a mean 0.511 percentage point decrease in glycemic level would, if maintained, produce a 10.7% reduction in diabetes complications (16) and an important improvement in diabetes morbidity with accompanying reductions in complication costs. However, these results should not breed complacency about the need for further efforts to achieve glycemic control. Although averages are improving, many individuals still are not meeting the optimal control targets, and A1C levels and rates of suboptimal control are especially high in some demographic groups. Moreover, our estimated reduction in A1C is only about half of the average 0.9 percentage point reduction achieved by intensive glycemic control in the UKPDS relative to conventional control (2), suggesting that more improvement is possible. Perhaps the best response to our results is a continuing effort to make even more progress in the future both for A1C and for other risk factors for diabetes complications.
